Portal de Periódicos da CAPES

Histiocytoses: emerging neoplasia behind inflammation

2017; Elsevier BV; Volume: 18; Issue: 2 Linguagem: Inglês

10.1016/s1470-2045(17)30031-1

1474-5488

Julien Haroche, F. Cohen Aubart, Barret J. Rollins, Jean Donadieu, Frédéric Charlotte, Ahmed Idbaïh, Augusto Vaglio, Omar Abdel‐Wahab, Jean‐François Emile, Zahir Amoura,

Extracellular vesicles in disease

Histiocytoses are disorders characterised by inflammation and the accumulation of cells derived from the monocyte and macrophage lineages, which results in tissue damage. Although they are often considered rare disorders with protean clinical manifestations, considerable advances in the understanding of their genetics have led to increased clinical recognition of these conditions, and fuelled further insights into their pathogenesis. In this Review, we describe insights into the cells of origin, molecular pathology, clinical features, and treatment strategies for some of the most common histiocytic disorders, including Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease. With the discovery of recurrent mutations affecting the mitogen-activated protein kinase and mTOR–AKT pathways in some of these histiocytoses, our understanding of these diseases has now evolved from the concept of a primary inflammatory condition to that of a clonal neoplastic disease. This understanding has led to the development of effective mechanism-based therapeutic strategies for patients with histiocytic diseases.